“Many innovative solutions are being proposed to help tackle the spread of counterfeit drugs in developing countries,” GlobalVoices reports. The blog includes highlights from several news articles and blog posts on the topic, including a number of solutions used to identify such drugs. The blog also includes a link to a TEDxBoston talk by Ashifi Gogo, an entrepreneur from Ghana, in which he “explains how his solution works by combining cell phones, community, and the cooperation of governments and pharmaceutical companies” (Rakotomalala, 8/30).
Devex reports on a panel discussion held in Washington, D.C. Wednesday during which experts “looked back at the main surprises of the just-concluded [XIX International AIDS Conference (AIDS 2012)], and offered predictions on what the 2014 follow-up [in Melbourne, Australia] will focus on.” The Center for Strategic and International Studies (CSIS) and the Kaiser Family Foundation convened the panel, which discussed, among other things, the so-called “cure agenda” and how it might feature in Melbourne, according to Devex. Chris Beyrer, president-elect of the International AIDS Society, which organizes the biannual event, noted that AIDS 2014 might place more focus on human rights and governance issues, according to the news service, which adds Greg Millet, senior policy adviser in the White House Office of National AIDS Policy, pointed out that HIV prevalence among men is higher in countries that criminalize homosexuality. “Holding the conference in Australia should increase participation by Asian countries, said J. Stephen Morrison, senior vice president and director of the Global Health Policy Center” at CSIS, Devex writes (Brookland, 8/2). Jennifer Kates, director of global health and HIV policy at the Kaiser Family Foundation, and David Brown, staff writer at the Washington Post, also participated as panelists, according to the CSIS event page (8/3).
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday “to champion innovative solutions to the world’s major health problems,” Imperial College London reports in an article, which notes the summit, “the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development” and “will tackle maternal health, primary care, non-infectious diseases and aging societies” (8/1). “This is a unique summit. We’re gathering the global thought leaders, very much to exchange ideas, to learn from each other, when it comes to innovative solutions to the significantly great challenges facing health care systems globally,” summit chair Ara Darzi of the Institute for Global Health Innovation tells BBC Radio correspondent Claudia Hammond in a “Health Check” audio report (8/1).
In this post in Huffington Post’s “Healthy Living” blog, John-Manuel Andriote, a journalist and author living with HIV, writes, “For all of us living with HIV infection — Oct. 27 will mark seven years since my own diagnosis — the question we face daily, hopefully more consciously and deliberately than most, is how shall we live, knowing as we do that we will most assuredly die one day?” Reflecting on the XIX International AIDS Conference (AIDS 2012) that took place in Washington last month, he continues, “An AIDS-free generation is certainly a worthy goal,” but “even if tens of billions of additional dollars are allocated to address HIV/AIDS, even if the Republicans don’t succeed in inflicting their Darwinian ‘survival of the fittest’ upon the nation and the world, the question will continue to be what it has been for 31 years … Will we have the political will to end AIDS?”
“As researchers from both sides of the debate over two controversial H5N1 studies weighed in [Tuesday] on full publication versus a more cautionary approach, two U.S. journals” — the Journal of Infectious Diseases (JID) and its sister publication, Clinical Infectious Diseases — “said they are developing policies to address any future such instances,” CIDRAP News writes. “We are developing policies that address these issues on a case-by-case basis, so that freedom of scientific expression can be maintained without sacrificing individual safety or national security,” JID Editor Martin Hirsch wrote in an editorial, the news service notes, adding, “He also introduced three new JID perspective pieces that discuss the difficult issues” (Schnirring, 3/28).
The Center for Global Health Policy’s “Science Speaks” blog reports the findings from the second edition of the 2011 Report on Tuberculosis (TB) Research Funding and Trends from 2005-2010, released Thursday by Treatment Action Group (TAG) and the Stop TB Partnership. “TB research and development investment increased 76 percent between 2005 and 2010, but investment has slowed markedly, with only two percent growth since 2009,” the blog notes, adding, “The $630.4 million 2010 investment is only one-third of the $2 billion needed to stay on track with the Global Plan to Stop TB 10-year implementation and research strategy to eliminate TB as a public health threat by 2050” (Mazzotta, 3/28).
The debate about two studies showing that, with few genetic mutations, H5N1 bird flu strains could become more easily transmissible among ferrets, a laboratory model for humans, “has become a debate about the role of science in society. Two questions should be addressed here: should this type of research be conducted at all; and if so, should all data generated by this research be published?” Ab Osterhaus, head of the Institute of Virology, at Erasmus Medical Centre in Rotterdam, writes in a Guardian opinion piece. A team from Erasmus conducted one of the two studies, he notes.
“To break free of its dependence on donor money and supplies from India, Africa must develop its own pharmaceutical pipeline by creating policy frameworks that encourage a fledgling drug industry,” journalist Priya Shetty argues in this SciDev.Net opinion piece. “Although India’s drug industry continues to churn out generics against killer diseases such as HIV/AIDS, malaria and tuberculosis, there is no end to resistance from global pharmaceutical companies wanting to extend the duration of market exclusivity on their brand-name drugs to prevent competition from generics,” she writes, and notes, “The Council on Health Research for Development (COHRED) forum, to be held in South Africa in April 2012, will discuss how resource-poor nations can become more self-sufficient.”
“The U.S. government [on Thursday] released a new policy [.pdf] that will require federal agencies to systematically review the potential risks associated with federally funded studies involving 15 ‘high consequence’ pathogens and toxins, including the H5N1 avian influenza virus,” Science Insider reports. “The reviews are designed to reduce the risks associated with ‘dual use research of concern’ (DURC) that could be used for good or evil,” the news service writes (Malakoff, 3/29).
Largest-Ever Study Of Community-Wide TB Drug Prevention Did Not Improve TB Control In South African Mines
“After seven years of research, the world’s largest study of preventative tuberculosis (TB) therapy has found that untargeted, community-wide distribution of TB prevention drugs did not improve TB control in South African gold mines,” PlusNews reports. “Conducted among 27,000 gold-mine employees in 15 mines, the Thibela TB study tested the theory that treating an entire community with the first-line TB drug isoniazid could result in long-lasting reductions in active TB cases and TB prevalence,” the news service writes (3/9). The study found that “provid[ing] community-wide isoniazid preventive therapy (IPT)” did “not improve TB control,” according to Health-e. “However, evidence showed that there were 63 percent fewer TB cases among individuals in the program during the first nine months of the program, providing reassurance that IPT works for people who take it,” the news service notes (Thom, 3/14).